PHERGAIN
OFFICIAL TITLE: CHEMOTHERAPY-FREE TRASTUZUMAB AND PERTUZUMAB IN HER2-POSITIVE (HUMAN EPIDERMAL RECEPTOR) BREAST CANCER: FDG-PET RESPONSE-ADAPTED STRATEGY. THE PHERGAIN STUDY
CLINICAL TRIAL DETAILS
THE STUDY ASSESS THE EARLY METABOLIC EFFECTS OF NEOADJUVANT TREATMENT WITH TRASTUZUMAB AND PERTUZUMAB (± ENDOCRINE THERAPY) ON THE PRIMARY TUMOR AND AXILLARY LYMPH NODES AND THEIR PREDICTIVE VALUE FOR PATHOLOGIC COMPLETE RESPONSE (PCR) IN THE BREAST AND AXILLA.
AND ALSO ASSESS 3-YEAR INVASIVE DISEASE-FREE SURVIVAL (IDFS) IN PATIENTS WITH HER2-POSITIVE (HER: HUMAN EPIDERMAL RECEPTOR) BREAST CANCER TREATED WITH NEOADJUVANT TRASTUZUMAB AND PERTUZUMAB (± ENDOCRINE THERAPY) USING A FDG-PET RESPONSE-ADAPTED STRATEGY.
​
​
PHERGAIN AT CLINICALTRIALS.GOV
TUMOR TYPE
PHASE
HER2+ EBC
II
377
56
Spain, Portugal, France, UK, Italia, Belgium, Germany
N
SITES
COUNTRY
STATUS
Analysis
PRESS RELEASE
SCIENTIFIC IMPACT
ESMO 2023 - HER2DX PHERGain substudy – DOWNLOAD THE POSTER
ESMO 2023 – HER2DX PHERGain substudy DOWNLOAD THE LAY LANGUAGE SUMMARY
ESMO 2023 – Trop-2 PHERGain substudy – DOWNLOAD THE POSTER
ESMO 2023 – Trop-2 PHERGain substudy – DOWNLOAD THE LAY LANGUAGE SUMMARY
ASCO 2023 – DOWNLOAD THE PRESENTATION
ASCO 2023 – DOWNLOAD THE LAY LANGUAGE SUMMARY
PHERGAIN CASE STUDY 2023 – DOWNLOAD
ESMO BREAST 2022 – DOWNLOAD THE SLIDES
SABCS 2017 – DOWNLOAD THE POSTER
Dr. Antonio Llombart highlighted the importance of translational studies within the PHERGain at ESMO 2023.
Dr. María Gion discusses the importance of biomarkers like Trop-2 in PHERGain's translational studies during the ESMO congress.
Don't miss exclusive interviews with the principal investigators of the groundbreaking PHERGain study.
BLOG ARTICLES RELATED
PHERGAIN SITES
Countries: Spain, Portugal, France, UK, Italia, Belgium, Germany